Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Келикс (пегилированный липосомальный доксорубицин) в программной терапии 2-й линии метастатического рака молочной железы
Келикс (пегилированный липосомальный доксорубицин) в программной терапии 2-й линии метастатического рака молочной железы. Онкология. 2006; 1: 71-72.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Cameron RB. Malignancies of the Breast. Chap. 53 in A Lange Clinical Manual – Practical Oncology 1st Edition. Norwalk: Appleton & Lange, 1994.
2. Skipper HE. Criteria Associated with Destruction of Leukemia and Solid Tumor Cells in Animals. Cancer Res 1967; 27:2636–45.
3. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
4. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
5. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460–64.
6. Data on File SEQUUS Nonclinical Toxicology Reports: LTI-30-93-24 (rats), LTI-30-94-14 (dogs), LTI-30-94-28 (rabbit).
7. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealthв Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
8. North D, et al. Pharmacokinetics (PK), Tumour Localization (TL) and Safety of CAELYX (Liposomal Doxorubicin ) in AIDS Patients with Kaposi’s Sarcoma (AIDS-KS). Proceedings from the American Society of Oncology, 1993; 12:51.
9. Vaage J, Mayhew E, Lasic D, et al. Therapy of Primary and Metastatic Mouse Mammary Carcinomas with Doxorubicin Encapsulated in Long Circulating Liposomes. Int. J. Cancer, 1992; 51:942–8.
10. Ozols RB, et al. Chemotherapy for Murine Ovarian Cancer: A Rationale for IP Therapy with Adriamycin. Cancer Treat Rep., 1979; 63:269–74.
11. Chavdury PM, Roninson IB. Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J Natl Cancer Institute, 1993; 85:632–9.
12. Ouclard S, et al. Sensitization of Multidrug-Resistant Colon Cancer Cells to Doxorubicin Encapsulated in Liposomes. Cancer Chemother Pharmacol, 1991; 28(4):259–65.
13. Thierry AR, et al. Effect of Liposomes on P Glycoprotein Function in Multidrug-Resistant Cells. Biochem-Biophys Res Commun, 1992; 187:1098–105.
14. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
15. Berry G, Billingham M, Torti F, et al. Reduced Cardiotoxicity in AIDS Kaposi’s Sarcoma Patients Treated with Pegylated Liposomal Doxorubicin (CAELYXв) as Compared to Conventional Doxorubicin. In preparation.
16. Muggia F., Hainsworth J., Jeffers S., et al. Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J. Clin. Oncol. Vol 15, No3 (March) 1997: p. 987–93
17. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12–15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
18. O’Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil)vs conventional doxorubicinfor first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440–9
2. Skipper HE. Criteria Associated with Destruction of Leukemia and Solid Tumor Cells in Animals. Cancer Res 1967; 27:2636–45.
3. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
4. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
5. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460–64.
6. Data on File SEQUUS Nonclinical Toxicology Reports: LTI-30-93-24 (rats), LTI-30-94-14 (dogs), LTI-30-94-28 (rabbit).
7. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealthв Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
8. North D, et al. Pharmacokinetics (PK), Tumour Localization (TL) and Safety of CAELYX (Liposomal Doxorubicin ) in AIDS Patients with Kaposi’s Sarcoma (AIDS-KS). Proceedings from the American Society of Oncology, 1993; 12:51.
9. Vaage J, Mayhew E, Lasic D, et al. Therapy of Primary and Metastatic Mouse Mammary Carcinomas with Doxorubicin Encapsulated in Long Circulating Liposomes. Int. J. Cancer, 1992; 51:942–8.
10. Ozols RB, et al. Chemotherapy for Murine Ovarian Cancer: A Rationale for IP Therapy with Adriamycin. Cancer Treat Rep., 1979; 63:269–74.
11. Chavdury PM, Roninson IB. Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J Natl Cancer Institute, 1993; 85:632–9.
12. Ouclard S, et al. Sensitization of Multidrug-Resistant Colon Cancer Cells to Doxorubicin Encapsulated in Liposomes. Cancer Chemother Pharmacol, 1991; 28(4):259–65.
13. Thierry AR, et al. Effect of Liposomes on P Glycoprotein Function in Multidrug-Resistant Cells. Biochem-Biophys Res Commun, 1992; 187:1098–105.
14. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
15. Berry G, Billingham M, Torti F, et al. Reduced Cardiotoxicity in AIDS Kaposi’s Sarcoma Patients Treated with Pegylated Liposomal Doxorubicin (CAELYXв) as Compared to Conventional Doxorubicin. In preparation.
16. Muggia F., Hainsworth J., Jeffers S., et al. Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J. Clin. Oncol. Vol 15, No3 (March) 1997: p. 987–93
17. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12–15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
18. O’Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil)vs conventional doxorubicinfor first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440–9
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.